# Nuclide record thyroid (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/thyroid/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "thyroid" ;
  schema:name "Thyroid cancer"@en ;
  schema:description "Thyroid cancer is usually curable with surgery and radioactive iodine, the original theranostic. Rare aggressive forms respond to RET and BRAF inhibitors."@en ;
  schema:url <https://nuclide.cc/indications/thyroid/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Thyroid_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q826522> ;
  schema:citation <https://en.wikipedia.org/wiki/Thyroid_cancer> ;
  nuclide:tag "endocrine", "spike" ;
  nuclide:related <https://nuclide.cc/roadmaps/radiopharma-roadmap/>, <https://nuclide.cc/terms/theranostics/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/radioiodine-therapy/> ;
  nuclide:drugs <https://nuclide.cc/drugs/radioactive-iodine/>, <https://nuclide.cc/drugs/thyrotropin-alfa/> ;
  nuclide:companies <https://nuclide.cc/companies/eli-lilly/>, <https://nuclide.cc/companies/bayer/>, <https://nuclide.cc/companies/novartis/>, <https://nuclide.cc/companies/astrazeneca/> ;
  nuclide:institutions <https://nuclide.cc/institutions/md-anderson/>, <https://nuclide.cc/institutions/mskcc/> ;
  nuclide:terms <https://nuclide.cc/terms/theranostics/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06860971/>, <https://nuclide.cc/trials/nct03690388/>, <https://nuclide.cc/trials/select-lenvatinib/>, <https://nuclide.cc/trials/decision-sorafenib/>, <https://nuclide.cc/trials/estimabl2/>, <https://nuclide.cc/trials/ion-trial/>, <https://nuclide.cc/trials/hilo/>, <https://nuclide.cc/trials/astra/> ;
  nuclide:pipeline <https://nuclide.cc/drugs/al2846/>, <https://nuclide.cc/drugs/pembrolizumab/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:standardOfCare <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/trials/estimabl2/>, <https://nuclide.cc/trials/ion-trial/>, <https://nuclide.cc/drugs/radioactive-iodine/>, <https://nuclide.cc/technologies/radioiodine-therapy/>, <https://nuclide.cc/trials/hilo/>, <https://nuclide.cc/trials/select-lenvatinib/>, <https://nuclide.cc/trials/decision-sorafenib/>, <https://nuclide.cc/drugs/pembrolizumab/> .